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iwo studies in this issue of the Journal report the effects of
ranulocyte-macrophage colony-stimulating factor (GM-
SF) and granulocyte colony-stimulating factor (G-CSF)
o promote coronary neovascularization; both were stopped
arly because of ominous results. In the report by Zbinden
t al. (1), GM-CSF (10 g/kg/day given subcutaneously for
wo weeks) was administered to patients with stable angina
efore undergoing percutaneous coronary intervention.
ithin 12 days of treatment, two of seven treated patients
eveloped an acute occlusion of a coronary artery (1). In the
tudy by Hill et al. (2), 2 of 16 patients with refractory
ngina treated with G-CSF (10 g/kg/day given subcuta-
eously for five days) suffered an acute myocardial infarc-
ion, which was fatal in one patient (2).
See pages 1636 and 1643
The ability to stimulate neovascularization is an attractive
oal for patients with a number of serious ischemic syn-
romes, such as refractory and stable angina, acute myocar-
ial infarction, critical limb ischemia, and claudication.
owever, measuring treatment effects and detecting unin-
ended complications has been difficult. Early therapeutic
ngiogenesis trials used agents that primarily stimulated
ngiogenesis (the growth of new capillaries from pre-
xisting ones). They demonstrated excellent safety but only
odest efficacy, prompting a shift in focus to agents that
timulate arteriogenesis (growth of larger, more mature
essels) (3,4).
In the race to develop more effective neovascularization,
-CSF and GM-CSF were attractive candidates because
hey appeared in animal models to stimulate arteriogenesis
irectly. In addition, they increased circulating progenitor
ells, which themselves may cause neovascularization in
schemic tissues by directly incorporating or by stimulating
ytokines. Moreover, these drugs already were approved for
se in large numbers of patients undergoing chemotherapy
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.t
From the †Cardiovascular Division, University of Minnesota and the ‡Minne-
polis Heart Institute Foundation, Minneapolis, Minnesota.or malignancies and for use in increasing circulating pro-
enitor cells in transplant donors.
We now have four published trials in which G-CSF/
M-CSF alone or in combination with local delivery of
rogenitor cells was given to promote neovascularization in
atients with atherosclerosis (1,2,5,6). Preclinical trials and
hese initial clinical studies suggest that G-CSF and GM-
SF are more effective when used in combination with the
ocal delivery of progenitor cells than when they are used
lone. Hill et al. (2) and Kang et al. (5) demonstrated no
ignificant benefit of G-CSF alone in patients with refrac-
ory angina and acute and chronic myocardial infarction,
espectively (2,5). In two other reports, Zbinden et al. (1)
nd Seiler et al. (6) reported an improvement in coronary
ow index in patients with stable angina treated with
M-CSF alone, but these findings are confounded by
he small sample size and the lack of improvement when
he treated and placebo groups are compared directly
1,6). The strongest indication for benefit comes from the
yoblast Autologous Grafting in Ischemic Cardiomyop-
thy (MAGIC) trial, in which a significant improvement
n left ventricular function, myocardial perfusion, and
readmill times was found in patients who received
ntracoronary delivery of progenitor cells after the admin-
stration of G-CSF (5).
Unfortunately, three of these four early trials were
topped early because of significant safety concerns. In
ddition to the apparent increase in acute coronary syn-
romes in the two trials reported in this issue of the Journal,
ang et al. (5) reported a marked increase in in-stent
estenosis in patients with acute myocardial infarction who
eceived G-CSF after percutaneous coronary intervention.
he mechanism for these complications is not clear, but
-CSF and GM-CSF both have proinflammatory and
rocoagulant effects, in addition to their potent arteriogenic
ctions (7).
Researchers have used G-CSF and GM-CSF extensively
o stimulate circulating progenitor cells both for patients
erving as donors and those with underlying malignancy in
ieu of more complex harvesting from the bone marrow
8–10). Some concern exists about safety in these patients also,
ncluding a number of case reports of acute myocardial infarc-
ion, unstable angina, and stroke in patients with and
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Editorial Comment November 1, 2005:1649–50ithout a history of previous myocardial infarction (10). An
ad-hoc” workshop convened with investigators in the field
ecommended the creation of an international cytokine-
obilized peripheral blood stem cell donor registry to
onitor the short- and long-term effects of the procedure
8). Some controversy also exists regarding the optimal dose,
ith one recommendation to not exceed 8.8 g/kg/day, but
oth the dose and time course remain controversial (8–10).
f note, all of the angiogenesis trials with excessive com-
lications have used 10 g/kg/day for as long as two weeks.
o cases of acute coronary syndrome have been reported in
hree ongoing clinical trials using lower doses of G-CSF, based
n personal communication with the trial investigators.
It is not surprising that these safety concerns were not
etected during preclinical testing. Infrequent complica-
ions can be nearly impossible to predict from large animal
tudies, in part because of natural biological differences and
n part due to the enormous costs of testing therapies in
arge numbers of animals with complex protocols (some-
imes exceeding the cost of human treatments). As a result,
any treatments go to market with limited, necessarily
mperfect animal model data.
In the case of GM-CSF, we may have been lucky because
he scientific community published their results, allowing
he rapid identification of a potential problem. It might be
fluke or it might only occur at higher doses, but we have
een alerted to the issue by honest clinical investigators.
The challenge for clinical investigators is to establish,
erhaps with the help of the Food and Drug Administra-
ion, a worldwide system for monitoring the safety of these
ew therapies. Many serious complications occur infre-
uently; without a coordinated clinical reporting system,
heir detection will occur randomly and late. Cardiovascular
nvestigators have been incredibly successful in collabora-
ively developing enormous clinical studies. We now should
upport a collaborative cardiovascular safety database where
nvestigators report therapeutic complications and the safety
f new therapies can be monitored across multiple studies.
On the basis of the reports in this Journal, in addition to
revious reports, it seems prudent to restrict ongoing trials
sing G-CSF or GM-CSF to patients with no otherherapeutic options, such as those with refractory angina or
ritical limb ischemia. Using a lower dose may be safer but
eeds confirmation. Additionally, we need to know more
bout the safety of G-CSF/GM-CSF in normal donors and
atients with malignancy, especially those with coronary
therosclerosis. Finally, the recommendation for the inter-
ational registry for growth factor therapy proposed previ-
usly should be implemented. These trials remind us again
f the delicate balance involved in the natural process of
ascular growth. For those without the option of revascu-
arization, therapeutic angiogenesis or arteriogenesis remain
ttractive-yet-elusive goals.
ddress for correspondence: Dr. Robert F. Wilson, MMC
08, 420 Delaware Street, SE, Minneapolis, Minnesota 55455.
-mail: wilso008@umn.edu.
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